Domestic patients can only choose to buy abroad, but the cost is higher. Take lalotinib as an example, the price of each bottle is more than 230,000 RMB, and with the cost of diagnosis and transportation, most patients can only sigh.
If there is anything more desperate than "hopeless", it is that there are specific drugs, but you can't buy them! Can't afford it!
Last year, after the release of information about clinical recruitment of lalotinib and emtrictinib in China, it attracted wide attention. Finally, after more than half a year's approval process, two broad-spectrum anticancer drugs, lalotinib and emtrictinib, both announced good news and officially recruited patients in China! This means that domestic patients finally have the opportunity to use these American anti-cancer "specific drugs" for free!
These experiments are all international multi-center experiments, in which China also participated, led by several authoritative hospitals in the field of cancer in China.
First, the recruitment information of emtrictinib adult solid tumor
This is an open, multi-center, global phase II basket study on Entrectinib in the treatment of locally advanced or metastatic solid tumor patients with NTRK 1/2/3, ROS 1 or ALK gene rearrangement, to determine the acceptability of each type of solid tumor patient population (basket) with NTRK 1 or ALK gene rearrangement.
Test classification: safety and effectiveness
Examination scope: international multi-center examination.
Test stage: the second stage
MAIN OUTCOME MEASURES: The best total remission rate was decided by the independent radiological review committee.
Membership conditions (partial):
1. Locally advanced or metastatic solid tumor is diagnosed by histology or cytology, and it is detected by any nucleic acid diagnostic detection method according to the local diagnostic laboratory certified by Foundation Medical Company or CLIA or equivalent institution. Tumor carries gene rearrangement of NTRK 1/2/3, ROS 1 or ALK, which is expected to be transformed into fusion proteins with functional TrkA/B/C, ROS 1 or ALK kinase domains respectively, and there is no second carcinogen (such as EGFR and KRAS).
2. For patients who have passed molecular testing in local laboratories, archive or fresh tumor tissues (unless there are medical contraindications) shall be submitted for independent central molecular testing in Foundation Medicine, Inc or other recognized central laboratories in the region;
3. According to the local assessment using RECIST v 1. 1, diseases can be measured.